FDG-PET/CT in the diagnosis of recurrent breast cancer

Acta Radiologica

Volumn 53, Issue 1, 2012, Pages 12-16

  Murakami, Ryusuke ^a   Kumita, Shin Ichiro ^a   Yoshida, Tamiko ^a   Ishihara, Keiichi ^a   Kiriyama, Tomonari ^a   Hakozaki, Kenta ^a   Yanagihara, Keiko ^a   Iida, Shinya ^a   Tsuchiya, Shin Ichi ^b  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b NIPPON MEDICAL SCHOOL HOSPITAL   (Japan)

Author keywords

Breast cancer; FDG; Metastasis; PET CT; Recurrence; Tumor marker

Indexed keywords

BREAST CANCER; FDG; METASTASIS; RECURRENCE; TUMOR MARKER;

COMPUTERIZED TOMOGRAPHY; DIAGNOSIS; DISEASES; TUMORS;

POSITRON EMISSION TOMOGRAPHY;

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BREAST TUMOR; DIFFERENTIAL DIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; PREDICTIVE VALUE; REPRODUCIBILITY; RETROSPECTIVE STUDY; SCINTISCANNING; SECOND CANCER; SENSITIVITY AND SPECIFICITY; TUMOR RECURRENCE;

ADULT; AGED; BREAST NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 84856524871     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.1258/ar.2011.110245     Document Type: Article

References (20)

1. Zangheri B, Messa C, Picchio M, et al. PET/CT and breast cancer. Eur J Nucl Med Mol Imaging 2004;31:135-42
2. Adler LP, Crowe JP, al-Kaisi NK, et al. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology 1993;187:743-50 (Pubitemid 23155705)
3. Wahl RL, Cody RL, Hutchins GD, et al. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1991;179:765-70
4. Nieweg OE, Kim EE, Wong WH, et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993;71:3920-5 (Pubitemid 23172970)
5. Avril N, Menzel M, Dose J, et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 2001;42:9-16 (Pubitemid 32104770)
6. Bombardieri E, Crippa F. PET imaging in breast cancer. Q J Nucl Med 2001;45:245-56 (Pubitemid 34182906)
7. Gallowitsch HJ, Kresnik E, Gasser J, et al. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol 2003;38: 250-6 (Pubitemid 36535030)
8. Grahek D, Montravers F, Kerrou K, et al. [18F]FDG in recurrent breast cancer: diagnostic performances, clinical impact and relevance of induced changes in management. Eur J Nucl Med Mol Imaging 2004;31:179-88 (Pubitemid 38173692)
9. Lonneux M, Borbath I, Berlière M, et al. The Place of Whole-Body PET FDG for the Diagnosis of Distant Recurrence of Breast Cancer. Clin Positron Imaging 2000;3:45-9
10. Suárez M, Pérez-Castejón MJ, Jiménez A, et al. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. Q J Nucl Med 2002;46:113-21
11. van der Hoeven JJ, Krak NC, Hoekstra OS, et al. 18F-2-fluoro-2-deoxy-d- glucose positron emission tomography in staging of locally advanced breast cancer. J Clin Oncol 2004;22: 1253-9 (Pubitemid 41079839)
12. Beyer T, Townsend DW, Brun T, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000;41:1369-79 (Pubitemid 30643379)
13. Mahner S, Schirrmacher S, Brenner W, et al. Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy- D-glucose, conventional imaging and computed tomography for staging breast cancer. Ann Oncol 2008;19:1249-54 (Pubitemid 351911953)
14. Aukema TS, Rutgers EJ, Vogel WV, et al. The role of FDG PET/CT in patients with locoregional breast cancer recurrence: A comparison to conventional imaging techniques. EJSO 2010;36:387-92
15. Haug AR, Schmidt GP, Klingenstein A, et al. F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography in the follow-up of breast cancer with elevated levels of tumor markers. J Comput Assist Tomogr 2007;31:629-34 (Pubitemid 47457683)
16. Dirisamer A, Halpern BS, Flöry D, et al. Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer. Eur J Radiol 2009;73:324-8
17. Bakheet SM, Saleem M, Powe J, et al. F-18 fluorodeoxyglucose chest uptake in lung inflammation and infection. Clin Nucl Med 2000;25: 273-8 (Pubitemid 30173877)
18. Shim SS, Lee KS, Kim BT, et al. Focal parenchymal lung lesions showing a potential of false-positive and false-negative interpretations on integrated PET/CT. Am J Roentgenol 2006;186:639-48 (Pubitemid 46100250)
19. Kitajima K, Murakami K, Yamasaki E, et al. Performance of FDG-PET/ CT in the diagnosis of recurrent endometrial cancer. Ann Nucl Med 2008;22:103-9 (Pubitemid 351328965)
20. Radan L, Ben-Haim S, Bar-Shalom R, et al. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer 2006;107:2545-51 (Pubitemid 44845606)